Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting.

Gene therapies for rare blood disorders show promise with reduced crises and improved life quality, despite high costs and slow adoption.

CAR T-cell therapy offers hope for multiple myeloma, showing efficacy in trials but challenges in antigen targeting and tumor infiltration.

CRISPR Therapeutics faces challenges despite FDA approval for a breakthrough therapy, with slow progress impacting stock performance.

Gene therapies are very labor intensive, so despite their life-saving potential, access to and utilization of these therapies is a challenge

On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars...

Uncover the reasons behind the limited adoption of gene therapies for sickle cell disease at the AMCP Nexus 2024.

Outcomes-based agreements can take away clinical uncertainties, so payers have a guarantee that they're not spending money on something...

Jeffrey Casberg discusses key upcoming biosimilars and specialty drugs, the impact of the Inflation Reduction Act on drug pricing, and...

issues affecting payer uptake and provider adoption of biosimilars in the US, such as economic considerations, clinical evidence, and market

Jeffrey Casberg, MS, RPh, senior vice president of pharmacy at IPD Analytics, discussed the FDA approvals of new drugs and pricing.

In an interview with Jeffrey Casberg, MS, RPh, he discusses 3 promising specialty drugs coming through the pipeline.

Jeffrey Casberg, RPh, MS, from IPD Analytics, explains why he believes policy changes and market forces are impacting the cost of drugs,...

Learn about promising drugs currently in the pharmaceutical pipeline and the impact of FDA interventions from IPD presenters.

Several drug manufacturers have announced price cuts on commonly prescribed insulin products. By Brock Bizzell and David Baker | Original...

Jeffrey Casberg, RPh, MS, examines upcoming generic and biosimilar competition in the pharmaceutical industry, showcasing certain drugs...

IPD Analytics speaks about key takeaways from the AJMC 2024 Annual Conference

IPD presents at the AMCP 2024 annual meeting discussing the current promise and future potential of gene and cell therapies.

IPD Analytics LLC. discusses the up to 50 generics that could be approved this year, including Victoza to treat patients with diabetes.

Jeffrey Casberg of IPD Analytics LLC, talks about how payers are thinking about weight-loss drugs.